Cargando…
4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp
Neisseria meningitidis serogroup B (MenB) is the leading cause of meningococcal meningitis and sepsis in industrialized countries, with the highest incidence in infants and adolescents. Two recombinant protein vaccines that protect against MenB are now available (i.e. 4CMenB and MenB-fHbp). Both vac...
Autores principales: | Veggi, Daniele, Bianchi, Federica, Santini, Laura, Lo Surdo, Paola, Chesterman, Chelsy C., Pansegrau, Werner, Bechi, Nicoletta, Huang, Ying, Masignani, Vega, Pizza, Mariagrazia, Rappuoli, Rino, Bottomley, Matthew J., Cozzi, Roberta, Maione, Domenico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556464/ https://www.ncbi.nlm.nih.gov/pubmed/33007046 http://dx.doi.org/10.1371/journal.ppat.1008882 |
Ejemplares similares
-
Crystal structure reveals vaccine elicited bactericidal human antibody targeting a conserved epitope on meningococcal fHbp
por: López-Sagaseta, Jacinto, et al.
Publicado: (2018) -
Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect
por: Ruiz García, Yara, et al.
Publicado: (2021) -
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal
por: Simões, Maria João, et al.
Publicado: (2017) -
Meningococcal B Vaccination (4CMenB) in Infants and Toddlers
por: Esposito, Susanna, et al.
Publicado: (2015) -
An Analysis of the Sequence Variability of Meningococcal fHbp, NadA and NHBA over a 50-Year Period in the Netherlands
por: Bambini, Stefania, et al.
Publicado: (2013)